Blueprint Medicines Corp

Blueprint Medicines — Investor Presentation (January 2018)

27 slides from Blueprint Medicines's investor presentation, Jan 8, 2018

  1. Slide 1: A blueprint for a healthier tomorrow

    A blueprint for a healthier tomorrow January 8, 2018

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

  3. Slide 3: A new way of looking at kinase medicines

    A new way of looking at kinase medicines Highly selective kinase medicines offer potential for improved potency, less off-target activity and increased probability of clinical success Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) (CSTI). The foregoin

  4. Slide 4: Proprietary library rapidly delivers transformative medicines

    Proprietary library rapidly delivers transformative medicines Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) (CSTI). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its content. 4 Identify highly selective i

  5. Slide 5: Clinical strategy to rapidly bring transformative medicines to patients

    Clinical strategy to rapidly bring transformative medicines to patients Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) (CSTI). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its content. 5 Genomic driver of

  6. Slide 6: Realizing our vision for Blueprint Medicines

    Realizing our vision for Blueprint Medicines * Includes up to 5 programs under the cancer immunotherapy collaboration with Roche. 6 2014 – 2015 STRATEGY LIBRARY TEAM 3 CLINICAL CANDIDATES WITH PROOF-OF-CONCEPT 2016 – 2017 CLINICAL CANDIDATES 4 TUMOR AGNOSTIC CLINICAL TRIALS 2 TUMOR TYPES & RARE DISE

  7. Slide 7: Robust pipeline of diverse clinical and preclinical stage assets

    Robust pipeline of diverse clinical and preclinical stage assets NSCLC, non-small cell lung cancer. 1 Phase 1 trial includes a basket cohort that consists of other advanced solid tumors with RET alterations. 2 Blueprint Medicines has U.S. commercial rights for up to two programs. Roche has worldwide

  8. Slide 8: 2018 key priorities and expected milestones

    2018 key priorities and expected milestones GIST, gastrointestinal stromal tumors. 8 avapritinib Portfolio Research Complete enrollment of registration-enabling trial in PDGFRα-driven GIST by mid-2018 Initiate Phase 3 trial versus regorafenib in 3L GIST in 1H 2018 Initiate registration-enabling Phas

  9. Slide 9: Avapritinib is a potential pipeline within a single investigational medicine

    Avapritinib is a potential pipeline within a single investigational medicine SM, systemic mastocytosis. 9 KIT & PDGFRα Gastrointestinal stromal tumors PDGFRα-driven GIST 3L+ GIST 2L GIST Combination therapy Systemic mastocytosis Advanced SM Smoldering SM Indolent SM Other KIT & PDGFRα-driven disease

  10. Slide 10: Potent and selective KIT and PDGFRα inhibition has potential to address medical needs in GIST

    Potent and selective KIT and PDGFRα inhibition with avapritinib has the potential to address important medical needs in GIST ORR, objective response rate; PFS, progression free survival. * Imatinib re-challenged. ** Represents estimated incidence of GIST patients (regardless of alteration) and PDGFR

  11. Slide 11: Tumor reduction and prolonged PFS observed in GIST patients with multiple KIT genotypes

    Tumor reduction and prolonged PFS observed in GIST patients with multiple KIT genotypes1 via central radiology review 1 KIT genotypes assessed by archival tumor and ctDNA.2 Kang et al. Lancet Oncol. 2013;14(12):1175–82. DCR, disease control rate; MTD, maximum tolerated dose; PD, progressive disease;

  12. Slide 12: Remarkable activity in PDGFRα D842-mutant GIST

    Remarkable activity in PDGFRα D842-mutant GIST via central radiology review 1 Cassier et al. Clin Cancer Res. 2012;18(16):4458–64. 2 Yoo et al. Cancer Res Treat. 2016;48(2):546–52 CR, complete response. Data previously presented in November 2017 at the CTOS Annual Meeting. Data cutoff: October 11, 2

  13. Slide 13: Safety results showed avapritinib was well-tolerated in patients with GIST

    Safety results showed avapritinib was well-tolerated in patients with GIST Data previously presented in November 2017 at the CTOS Annual Meeting. Data cutoff: October 11, 2017. Cognitive effects are an aggregated category of individual cognitive events, each of which was observed in fewer than 20% o

  14. Slide 14: Ongoing and planned avapritinib clinical trials in patients with GIST

    Ongoing and planned avapritinib clinical trials in patients with GIST 14 Key Part 2 goals: safety, ORR, duration of response Key goals: PFS, ORR, safety Phase 1 clinical trial Status: recruiting Phase 3 clinical trial Status: plan to initiate in 1H 2018 Open-label dose escalation (3+3) PDGFR D842V

  15. Slide 15: Avapritinib clinical development program in GIST is rapidly advancing

    Avapritinib clinical development program in GIST is rapidly advancing NDA, new drug application. Data previously presented in November 2017 at the CTOS Annual Meeting. Data cutoff: October 11, 2017. Key Next Steps Complete enrollment of registration-enabling Phase 1 trial in PDGFRα-driven GIST by mi

  16. Slide 16: Systemic mastocytosis spectrum and patient populations

    SM with Associated Hematologic Neoplasm (SM-AHN) Aggressive SM (ASM) Mast Cell Leukemia (MCL) Advanced SM ~16,100 patients ~1,800 patients ~2,600 patients 1Garcia-Montero AC et al, 2006. 2Represents estimated prevalence regardless of alteration in major countries (US, EU5 and Japan). 3Based on publi

  17. Slide 17: Consistent clinical activity in systemic mastocytosis across outcome measures

    Consistent clinical activity in systemic mastocytosis across outcome measures regardless of dose, disease subtype, prior midostaurin or presence of additional mutations Data previously presented in December 2017 at the American Societyy of Hematology (ASH) Annual Meeting. Data cutoff: October 4, 201

  18. Slide 18: Best response in advanced systemic mastocytosis

    Best response2 n (%) (confirmed and unconfirmed) ASM (n=7) SM-AHN3 (n=8) MCL (n=3) Overall (n=18) Overall response rate (CR + PR + CI) 6 (86) 5 (63) 2 (67) 13 (72) CR + PR 5 (71) 4 (50) 1 (33) 10 (56) Complete response (CR) 2 (29) 0 0 2 (11) Partial response (PR) 3 (43) 4 (50) 1 (33) 8 (44) Clinical

  19. Slide 19: Safety results showed avapritinib was well-tolerated in patients with systemic mastocytosis

    Safety results showed avapritinib was well-tolerated in patients with systemic mastocytosis Data previously presented in December 2017 at the ASH Annual Meeting. Data cutoff: October 4, 2017. Most adverse events (AEs) reported by investigators were Grade 1 or 2 The most common treatment-emergent AEs

  20. Slide 20: A strong foundation for development of avapritinib in systemic mastocytosis

    A strong foundation for development of avapritinib in systemic mastocytosis Data previously presented in December 2017 at the ASH Annual Meeting. Data cutoff: October 4, 2017. Key Next Steps Plan to engage global regulatory authorities on registration pathways in 1H 2018 Pending regulatory feedback,

  21. Slide 21: Growing portfolio of highly selective investigational kinase medicines

    Growing portfolio of highly selective investigational kinase medicines 21 BLU-554 Hepatocellular carcinoma FGFR4 BLU-667 Non-small cell lung cancer Medullary thyroid cancer Other RET-altered solid tumors BLU-782 Fibrodysplasia ossificans progressiva RET ALK2

  22. Slide 22: Opportunity for selective FGFR4 inhibition with BLU-554 in hepatocellular carcinoma

    Significant opportunity for selective FGFR4 inhibition with BLU-554 in evolving hepatocellular carcinoma landscape 22 Potential future treatment paradigm nivolumab BLU-554 +/- immune checkpoint inhibitor Other TKIs FGFR4-driven HCC (~30% of patients) Planned next steps Initiate TKI-naïve cohort in o

  23. Slide 23: Preliminary Phase 1 results expected in 1H 2018 for BLU-667

    Preliminary Phase 1 trial results expected in 1H 2018 for BLU-667, a highly selective inhibitor of RET fusions and mutations 23 Phase 1 clinical trial Status: recruiting Open-label dose escalation RET-altered NSCLC with prior TKI (n=~20) Other RET-altered solid tumors (n=~20) Part 1 ongoing RET-alte

  24. Slide 24: BLU-782 selected as development candidate for fibrodysplasia ossificans progressiva

    BLU-782 selected as development candidate for potential treatment of fibrodysplasia ossificans progressiva 24 Devastating, ultra-rare genetic disease caused by mutant ALK2 Characterized by abnormal transformation of skeletal muscle, ligaments and tendons into bone Progressive loss of mobility and re

  25. Slide 25: Cash to fund operating expenses and capital expenditures into mid-2020

    Cash to fund operating expenses and capital expenditures into mid-2020* * Cash guidance gives effect to estimated net proceeds received upon closing of underwritten public offering on December 15, 2017 but excludes any potential option fees and milestone payments under the existing collaboration wit

  26. Slide 26: Full summary of expected 2018 milestones

    Full summary of expected 2018 milestones 26 Program Milestone Anticipated Timing avapritinib GIST Initiate Phase 3 trial in 3L GIST for avapritinib compared to regorafenib 1H 2018 Explore expedited clinical development pathways for KIT-driven GIST with regulatory authorities 1H 2018 Complete enrollm

  27. Slide 27: Thank you

    Thank you

Blueprint Medicines — Investor Presentation (January 2018) on 6ix